SCHEMBL689849

SCHEMBL689849

Cc1cccc(N)c1C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD44 P16070 1/20 0.48
CYP3A4 P08684 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
TSHR P16473 2/20 0.42
PIK3CA P42336 1/20 0.42
EPHB4 P54760 3/20 0.42
PARP1 P09874 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 2/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
BRD4 O60885 1/20 0.38
MYC P01106 1/20 0.37
DPP4 P27487 1/20 0.37
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2B P41595 1/20 0.37
USP2 O75604 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311565 0.86 PARP1 (0.46) CYP3A4TDP1TSHREPHB4PARP1
SCHEMBL28012101 0.84 IKBKB (0.46) CD44CYP3A4TDP1EPHB4L3MBTL1
SCHEMBL1613338 0.84 MMP2 (0.43) CYP3A4TDP1TSHRPIK3CAPARP1
SCHEMBL221626 0.83 TDP1 (0.52) CD44CYP3A4TDP1TSHRPIK3CA
SCHEMBL30590428 0.83 CD44 (0.48) CD44CYP3A4TDP1TSHRPIK3CA
SCHEMBL4058388 0.83 CD44 (0.48) CD44CYP3A4TDP1TSHRPIK3CA
Hydrochloric Acid SCHEMBL7442929 0.81 TDP1 (0.50) CD44CYP3A4TDP1TSHRPIK3CA
SCHEMBL7911668 0.81 CD44 (0.46) CD44CYP3A4TDP1TSHRPIK3CA
SCHEMBL27551460 0.80 TDP1 (0.42) CYP3A4TDP1TSHREPHB4PARP1
SCHEMBL18209596 0.79 CD44 (0.45) CD44CYP3A4TDP1TSHRPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0465340-B2 Keratinous fibres dyeing process with 4-hydroxyindol at acidic pH and compositions OREAL (FR) 1997-03-05 EP claimed
EP-0465340-A1 Keratinous fibres dyeing process with 4-hydroxyindol at acidic pH and compositions L'OREAL (FR) 1992-01-08 EP claimed
EP-0295474-A1 Chlorometaphenylenediamines, their use as coupling agents in oxydation colouring of keratinic fibres, colourity compositions for hair containing these compounds and colouring process using these compositions L'OREAL (FR) 1988-12-21 EP claimed
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP disclosed
US-20240190828-A1 Small Molecule Inhibitors of PBRM1-BD2 NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-13 US disclosed
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2024-05-28 US disclosed
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 US disclosed
EP-4291195-A1 SMALL MOLECULE INHIBITORS OF PBRM1-BD2 The Medical College of Wisconsin, Inc. (US) 2023-12-20 EP disclosed
US-11788080-B2 Modified cleavases, uses thereof and related kits Encodia, Inc. (US) 2023-10-17 US disclosed
US-20230257727-A1 MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2023-08-17 US disclosed
US-20230220589-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2023-07-13 US disclosed
WO-2005097750-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2005-10-20 WO disclosed
US-6562830-B1 Compounds which prevent or induce the remission of existing precancerous or cancerous lesions or carcinomas would greatly reduce illness and death from cancer CELL PATHWAYS, INC. 2003-05-13 US disclosed
EP-0628032-B1 QUINAZOLINONE ANTIANGINAL AGENTS PFIZER LTD (GB) 1998-05-13 EP disclosed
US-5482941-A Quinazolinone antianginal agents PFIZER INC. (US) 1996-01-09 US disclosed
EP-0628032-A1 QUINAZOLINONE ANTIANGINAL AGENTS Pfizer Limited (GB) 1994-12-14 EP disclosed
EP-0263523-B1 Process for the preparation of thiazolo [2,3-b] quinazolones BASF AG (DE) 1993-12-29 EP disclosed
WO-1993012095-A1 QUINAZOLINONE ANTIANGINAL AGENTS PFIZER LIMITED (GB) 1993-06-24 WO disclosed
US-5030727-A Reacting an anthronilide derivative with a thiazole derivative or a fluorozuinazolone with a neucleophile BASF AKTIENGESELLSCHAFT (DE) 1991-07-09 US disclosed
EP-0263523-A2 Process for the preparation of thiazolo [2,3-b] quinazolones BASF Aktiengesellschaft (DE) 1988-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors PARP1, PARP2, PARP11 CD44 1957/4885CYP3A4 2022/4885TDP1 40/4885
US-20240190828-A1 Small Molecule Inhibitors of PBRM1-BD2 BRD2, PBRM1, BRDT CD44 4472/4885CYP3A4 4379/4885TDP1 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.